Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 21 of 21 entries
View as:

A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05492045 Org: User:
Start: 09/13/22 End: 06/14/24 Due: 06/14/25

Evaluation of PK and Safety of D-0120 and Allopurinol

Phase: N/A Priority: Normal
NCT ID: NCT05360628 Org: User:
Start: 11/01/21 End: 07/23/22 Due: 07/23/23

Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients

Phase: N/A Priority: Normal
NCT ID: NCT05504083 Org: User:
Start: 09/28/22 End: 05/18/24 Due: 05/18/25

D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03291782 Org: User:
Start: 09/13/17 End: 08/06/18 Due: 08/06/19

D-0316 First Time in Patients Ascending Dose Study

Phase: N/A Priority: Normal
NCT ID: NCT03452150 Org: User:
Start: 01/03/18 End: 12/31/20 Due: 12/31/21

Study to Evaluate D-1553 in Subjects With Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05383898 Org: User:
Start: 03/16/21 End: 05/17/24 Due: 05/17/25

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03861156 Org: User:
Start: 02/28/19 End: 05/31/23 Due: 05/31/24

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05379946 Org: User:
Start: 10/12/22 End: 12/31/25 Due: 12/31/26

Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06233916 Org: User:
Start: 12/08/23 End: 01/10/24 Due: 01/10/25

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout

Phase: N/A Priority: Normal
NCT ID: NCT05665699 Org: User:
Start: 04/17/23 End: 12/30/25 Due: 12/30/26

D-0120 Safety and PK/PD Study in China

Phase: N/A Priority: Normal
NCT ID: NCT03923868 Org: User:
Start: 04/18/19 End: 12/31/21 Due: 12/31/22

Food Effect Study of D-0502 Tablet in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03810625 Org: User:
Start: 10/23/18 End: 04/17/19 Due: 04/17/20

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03471663 Org: User:
Start: 03/18/18 End: 10/18/23 Due: 10/18/24

Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04097405 Org: User:
Start: 09/18/19 End: 11/18/20 Due: 11/18/21

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06954961 Org: User:
Start: 09/15/22 End: 12/31/28 Due: 12/31/29

Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT06278350 Org: User:
Start: 01/31/24 End: 11/01/24 Due: 11/01/25

Study to Evaluate D-1553 in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04585035 Org: User:
Start: 10/02/20 End: 12/31/25 Due: 12/31/26

A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

Phase: N/A Priority: Normal
NCT ID: NCT06105255 Org: User:
Start: 05/24/23 End: 02/02/24 Due: 02/02/25

A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT07035041 Org: User:
Start: 05/22/25 End: 12/31/26 Due: 12/31/27

Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05226338 Org: User:
Start: 10/27/21 End: 05/11/22 Due: 05/11/23

Study in Healthy Adult Female Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05339633 Org: User:
Start: 03/29/22 End: 10/31/22 Due: 10/31/23